Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar 11;9(5):1210-1212.
doi: 10.1182/bloodadvances.2024015355.

Consensus in CLL: global needs matter

Mazyar Shadman  1   2 , Bita Fakhri  3 , Nitin Jain  4
Affiliations
Editorial

Consensus in CLL: global needs matter

Mazyar Shadman et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.S. has received consulting fees from, and served on advisory boards, steering committees, or data safety monitoring committees of AbbVie, Genentech, AstraZeneca, Genmab, Janssen, BeiGene, Bristol Myers Squibb (BMS), Kite Pharma, Eli Lilly, Fate Therapeutics, Nurix, and Merck; and has received research funding from Mustang Bio, Genentech, AbbVie, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, Vincerx, and BMS (spouse). B.F. has received research funding from Angiocrine, AbbVie, BMS/Juno, BeiGene, Genmab, Genentech, and Loxo Oncology; and has served on advisory boards of, received consulting fees from, or received honoraria from AbbVie, ADC Therapeutics, Adaptive Biotechnologies, AstraZeneca, BMS, BeiGene, Eli/Lilly, Genentech, Genmab, and Pharmacyclics. N.J. has received research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite/Gilead, MingSight, Takeda, Medisix, Loxo Oncology, NovalGen, Dialectic Therapeutics, Newave, Novartis, Carna Biosciences, Sana Biotechnology, and KisoJi Biotechnology; and has served on advisory boards of, or received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite/Gilead, Precision Biosciences, BeiGene, Cellectis, MEI Pharma, Ipsen, CareDx, MingSight, Autolus, and NovalGen.

Figures

None
Development of resource-specific guidelines for CLL. BCL2, B-cell lymphoma 2.
See this image and copyright information in PMC

Comment on

References

    1. Soumerai JD, Barrientos JC, Ahn IE, et al. Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2025;9(5):1213–1229. - PubMed
    1. Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918–932. - PubMed
    1. Jain N, Wierda WG, O'Brien S. Chronic lymphocytic leukaemia. Lancet. 2024;404(10453):694–706. - PubMed
    1. Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States. JCO Glob Oncol. 2020;6:1124–1133. - PMC - PubMed
    1. Al Sukhun S, Koczwara B, Temin S, Arun BK. Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline Q and A. JCO Glob Oncol. 2024;10 - PMC - PubMed